A Single Arm, Multicenter, Phase 2 Study of BGB-A317 as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma
Phase of Trial: Phase II
Latest Information Update: 01 Nov 2019
Price : $35 *
At a glance
- Drugs Tislelizumab (Primary)
- Indications Hodgkin's disease
- Focus Registrational; Therapeutic Use
- Sponsors BeiGene
- 24 Sep 2019 Planned End Date changed from 1 Jun 2020 to 31 Dec 2019.
- 13 Jun 2019 According to an BeiGene media release, the company will Host Investor Conference Call and Webcast to discuss Mid-2019 Clinical Data Updates.
- 13 Jun 2019 Results published in the BeiGene Media Release.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History